ReviewBrain tumor pathology2016
Cancer metabolism as a central driving force of glioma pathogenesis.
Review in Brain tumor pathology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 42 citations in OpenAlex.
- HAT1 as a Lactyltransferase to Promote DNA Repair Through RPA1 Lactylation in Glioblastoma.International journal of biological sciences · 2026Article
- Lactate reprograms glioblastoma immunity through CBX3-regulated histone lactylation.The Journal of clinical investigation · 2024Article
- Identification and Validation of a PEX5-Dependent Signature for Prognostic Prediction in Glioma.Biomolecules · 2024Article
- Strength of spatial correlation between gray matter connectivity and patterns of proto-oncogene and neural network construction gene expression is associated with diffuse glioma survival.Frontiers in neurology · 2024Article
- Strength of spatial correlation between structural brain network connectivity and brain-wide patterns of proto-oncogene and neural network construction gene expression is associated with diffuse glioma survival.medRxiv : the preprint server for health sciences · 2023Article
- Alterations in cellular metabolism under different grades of glioma staging identified based on a multi-omics analysis strategy.Frontiers in endocrinology · 2023Review
- The metabolomic landscape plays a critical role in glioma oncogenesis.Cancer science · 2022Review
- Multi-tracer and multiparametric PET imaging to detect the IDH mutation in glioma: a preclinical translational in vitro, in vivo, and ex vivo study.Cancer imaging : the official publication of the International Cancer Imaging Society · 2022Article
- Review
- Comprehensive analysis of PLOD family members in low-grade gliomas using bioinformatics methods.PloS one · 2021Article
- Codependency of Metabolism and Epigenetics Drives Cancer Progression: A Review.Acta histochemica et cytochemica · 2020Review
- The Sociobiology of Brain Tumors.Advances in experimental medicine and biology · 2020Review
- Capture at the single cell level of metabolic modules distinguishing aggressive and indolent glioblastoma cells.Acta neuropathologica communications · 2019Article
- IDH Mutation Analysis in Glioma Patients by CADMA Compared with SNaPshot Assay and two Immunohistochemical Methods.Pathology oncology research : POR · 2019Article
- The effect of the mTOR inhibitor rapamycin on glucoCEST signal in a preclinical model of glioblastoma.Magnetic resonance in medicine · 2019Article
- An Adult Drosophila Glioma Model for Studying Pathometabolic Pathways of Gliomagenesis.Molecular neurobiology · 2019Article
- mTOR Complexes as a Nutrient Sensor for Driving Cancer Progression.International journal of molecular sciences · 2018Review
- Glioma Grading and Determination of IDH Mutation Status and ATRX loss by DCE and ASL Perfusion.Clinical neuroradiology · 2018Article
- Glioblastoma: new therapeutic strategies to address cellular and genomic complexity.Oncotarget · 2018Review
- Identification of metabolism-associated genes and pathways involved in different stages of clear cell renal cell carcinoma.Oncology letters · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
The recent identification of distinct genetic and epigenetic features in each glioma entity is leading to a multilayered, integrated diagnostic approach combining histologic features with molecular genetic information. Somatic mutations in isocitrate dehydrogenase (IDH) and receptor tyrosine kinase (RTK) pathways are key oncogenic events in diffuse gliomas, including lower grade (grade II and III) gliomas (LGG) and the highly lethal brain tumor glioblastoma (GBM), respectively, where they reprogram the epigenome, transcriptome, and metabolome to drive tumor growth. However, the mechanisms by which these genetic aberrations are translated into the aggressive nature of gliomas through metabolic reprogramming have just begun to be unraveled. The intricate interactions between the oncogenic signaling and cancer metabolism have also been recently demonstrated. Here, we describe a set of recent discoveries on cancer metabolism driven by IDH mutation and mutations in RTK pathways, highlighting the integration of genetic mutations, metabolic reprogramming, and epigenetic shifts, potentially providing new therapeutic opportunities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.